Advertisement

Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography

  • J. Fritze
  • Th. Becker
  • V. Ziegler
  • G. Laux
  • P. Bieck
  • E. Sofic
  • P. Riederer
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 32)

Summary

In an open clinical trial 13 depressives significantly improved under the reversible and selective type-A monoamine oxidase (MAO) inhibitor brofaromine. The inhibitory potency of deproteinated plasma on a crude MAO preparation from human placenta was measured as a parameter for plasma brofaromine. There were no significant differences in plasma MAO inhibitory potency between responders (improvement > 50%; n = 5) and non-responders. MAO inhibitory potency significantly (p < 0.05) increased parallel to the increase of the dosage from 50 mg b.i.d. to t.i.d. confirming the validity of this technique. The biologic assay, however, overestimated brofaromine by a factor of two in acute kinetic experiments with healthy volunteers as compared to a Chromatographic technique, although both methods significantly correlated (r = 0.928).

Keywords

Monoamine Oxidase Human Placenta Inhibitory Potency Dysthymic Disorder Endogenous Depression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brotman AW, Falk WE, Gelenberg AJ (1987) Pharmacologic treatment of acute depressive subtypes. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1031–1040.Google Scholar
  2. Giambalvo CT (1984) Purification of endogenous modulators of monoamine oxidase from plasma. Biochem Pharmacol 33:3929–3932.PubMedCrossRefGoogle Scholar
  3. Glover V, Reveley MA, Sandier M (1980) A monoamine oxidase inhibitor in human urine. Biochem Pharmacol 29:467–470.PubMedCrossRefGoogle Scholar
  4. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.PubMedCrossRefGoogle Scholar
  5. Hengen N, Jedrychowski ME, Hoffmann E (1984) Pharmacokinetics of CGP 11 305A in man after acute and prolonged oral treatment. In: Tipton KF, Dostert P, Strolin-Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 185–191.Google Scholar
  6. Keller HH, Kettler R, Keller G, Da Prada M (1987) Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclo-bemide and Ro 16-6491. Naunyn-Schmiedebergs Arch Pharmacol 335:12–20.PubMedCrossRefGoogle Scholar
  7. Nakano T, Saito S, Higashida H, Kojima K, Nagatsu T (1986) Assignment of A and B types of monoamine oxidase in NCB20 hybrid cells to those of the parental cells by peptide mapping. J Neurochem 46:686–694.PubMedCrossRefGoogle Scholar
  8. Quitkin F, Rifkin A, Klein DF (1979) Monoamine oxidase inhibitors. Arch Gen Psychiatry 36:749–760.PubMedCrossRefGoogle Scholar
  9. Rudorfer MV, Potter WZ (1987) Pharmacokinetics of antidepressants. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1353–1363.Google Scholar
  10. Schiwy W, Heath WR, Delini-Stula A (1990) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose finding trials in depressed patients. J Neural Transm [Suppl] 28:33–44.Google Scholar
  11. Steiger A, Holsboer F, Gerken A, Demisch L, Benkert O (1987) Results of an open clinical trial of brofaromine (CGP 11 305 A), a competetive, selective, and short-acting inhibitor of MAO-A in major endogenous depression. Pharmacopsychiatry 20:262–269.PubMedCrossRefGoogle Scholar
  12. Szutowicz A, Kobes RD, Orsulak PJ (1984) Colorimetric assay for monoamine oxidase in tissues using peroxidase and 2,2′-azinodi-(3-ethyl-benzthiazoline-6-sulfonic acid) as chromogen. Anal Biochem 138:86–94.PubMedCrossRefGoogle Scholar
  13. Waldmeier PC, Baumann PA, Delini-Stula A, Bernasconi R, Sigg K, Buech O, Feiner AE (1983) Characterization of a new, short-acting and specific inhibitor of type A monoamine oxidase. Mod Probl Pharmacopsychiatry 19:31–52.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • J. Fritze
    • 1
  • Th. Becker
    • 1
  • V. Ziegler
    • 1
  • G. Laux
    • 1
  • P. Bieck
    • 2
  • E. Sofic
    • 1
  • P. Riederer
    • 1
  1. 1.Department of PsychiatryUniversity of WürzburgWürzburgFederal Republic of Germany
  2. 2.Institute of Human PharmacologyCiba-GeigyTübingenFederal Republic of Germany

Personalised recommendations